Antigen release is essential to initiate antitumor immunity, but how this step is regulated during metastatic dissemination has been unclear. The authors report that circulating tumor cells undergoing vascular migration shed migrasomes, organelles enriched in tumor-associated antigens, including cancer–testis and mutated antigens. These migrasomes travel to secondary lymphoid organs and are efficiently captured by antigen-presenting cells (APCs), which cross-present migrasome-derived antigens to activate CD8+ T cells. The resulting T cell responses constrain metastatic progression. Genetic blockade of migrasome formation enhanced metastasis, while administration of purified cancer-derived migrasomes restored immune-mediated suppression of metastatic growth. The data identify migrasomes as a metastasis-specific platform for endogenous tumor antigen delivery that can paradoxically unmask tumor immunogenicity during dissemination.
Metastasis remains the principal cause of cancer mortality and represents a phase when malignant cells disseminate and often evade immune elimination. Effective antitumor immunity depends on release and presentation of tumor antigens, a process traditionally associated with tumor cell death (for example, immunogenic cell death) or shedding of extracellular vesicles such as exosomes. Tumor-derived extracellular vesicles have complex, context-dependent effects on immunity: they can carry immunosuppressive cargo (for instance PD-L1) that facilitates immune evasion, but they can also deliver tumor antigens and proinflammatory signals that prime T cell responses.
Migrasomes are a recently described organelle produced by migrating cells. They bud from long retraction fibers left behind as cells move and encapsulate diverse cytosolic contents. Migrasomes have been implicated in intercellular communication in development and disease, and prior observations have noted migrasomes accompanying metastasizing tumor cells and ferrying immune-regulatory proteins such as PD-L1. The authors tested whether migrasomes released during vascular migration of circulating tumor cells could serve as a previously unrecognized mechanism of antigen release that activates antitumor immunity.
To probe factors influencing metastasis and migrasome biology, the study used the 4T1 mouse mammary carcinoma model, widely used as a model of aggressive triple-negative breast cancer. The investigators generated luciferase-expressing 4T1 derivatives with genetic loss of the tetraspanin Tspan4 (Tspan4−/−) and lines overexpressing Tspan4 (Tspan4 OE). When these cells were injected intravenously into syngeneic BALB/c mice and metastatic burden was imaged by IVIS at day 14 after D-Luciferin administration, mice receiving Tspan4−/− cells displayed significantly increased metastatic burden, whereas mice receiving Tspan4 OE cells showed markedly reduced metastatic burden. Survival data reported by the authors were consistent with these imaging results: Tspan4 deficiency shortened survival and overexpression prolonged survival of tumor-bearing mice.
Notably, manipulating Tspan4 did not alter primary tumor growth in subcutaneous models in either immunocompetent BALB/c or immunodeficient BALB/c-nude mice, indicating that Tspan4 selectively affects metastatic dissemination rather than primary tumor proliferation. These findings linked Tspan4 to regulation of metastasis and to production of migrasomes during dissemination, as summarized in the figures and text of the original article.
The authors report that migrasomes shed by migrating tumor cells are enriched in tumor-associated antigens, including cancer–testis and mutated antigens. These migrasomes traffic to secondary lymphoid organs, where they are preferentially phagocytosed by APCs. APCs that capture migrasome-derived antigens engage in cross-presentation, leading to activation of CD8+ T cells and generation of antitumor cytotoxic responses that limit metastatic outgrowth. The work positions migrasomes as an efficient, metastasis-linked vehicle for endogenous antigen delivery to the adaptive immune system.
Functionally, genetic inhibition of migrasome formation increased metastatic progression in the experimental systems described, demonstrating that migrasome-mediated antigen release contributes to immune-mediated constraint of metastasis. Conversely, administration of purified cancer-derived migrasomes restored immune suppression of metastatic growth in settings where migrasome formation had been impaired. These complementary approaches support a model in which migrasomes released during metastasis can enhance antitumor immunity rather than solely promote immune evasion.
The study reveals a paradox in which metastatic dissemination can enhance tumor immunogenicity through migrasome-mediated antigen release. Migrasomes represent a distinct and potent platform for delivering endogenous tumor antigens to APCs and eliciting CD8+ T cell responses that constrain metastatic outgrowth. The tetraspanin Tspan4 modulates this axis by regulating metastatic burden and migrasome production in the 4T1 breast cancer model. These findings expand understanding of how extracellular vesicle biology intersects with metastatic progression and antitumor immunity and identify migrasomes as a metastasis-specific mediator with potential implications for cancer immunobiology and therapeutic strategies. Specific experimental details, quantitative results, and full methodological descriptions are reported in the original article.